January 23, 2019
Rose
But Johnson & Johnson said it expects its sales growth to slow in 2019. Meanwhile, the company has agreed to pay $120 million to resolve claims over deceptive marketing.
from Kaiser Health News http://bit.ly/2S1Gczr
January 23, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
The Outgoing Senate Finance Committee Chair Was A Pharma Ally. The New One Is Not As Friendly To Drugmakers.- Mississippi’s 15-Week Abortion Ban ‘Unequivocally’ Unconstitutional, Judge Rules
- Internal VA Watchdog Finds Widespread Errors In Benefits Claims From Veterans Who Have ALS
- Walgreens, Humana Consider Deal As Industry Players Hunt For Merger Opportunities In Rapidly Evolving Health Landscape
- Perspectives: FDA’s Faster Pace At Approving Generics Has Saved Americans $26B, Yet It’s Flown Under Radar
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment